Hepatocellular adenoma: Difference between revisions
Line 50: | Line 50: | ||
{{MedCondContrAbs | {{MedCondContrAbs | ||
|MedCond =Hepatic adenoma|Norethindrone acetate and Ethinyl estradiol}} | |MedCond =Hepatic adenoma|Norethindrone acetate and Ethinyl estradiol|Norgestimate and Ethinyl estradiol}} | ||
{{Epithelial neoplasms}} | {{Epithelial neoplasms}} |
Revision as of 18:44, 23 October 2014
For patient information, click here
Hepatocellular adenoma | |
MRI: T2 Fat sat. A patient with multiple adenoma. Image courtesy of RadsWiki | |
ICD-O: | Template:ICDO |
DiseasesDB | 5726 |
MeSH | D018248 |
Hepatocellular adenoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hepatocellular adenoma On the Web |
American Roentgen Ray Society Images of Hepatocellular adenoma |
Risk calculators and risk factors for Hepatocellular adenoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., PhD.
Synonyms and keywords: Hepadenoma; hepatic adenoma
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Screening
Differentiating Hepatocellular adenoma from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Staging | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Contraindicated medications
Hepatic adenoma is considered an absolute contraindication to the use of the following medications: